Literature DB >> 1484146

Liver fibrosis in genetic hemochromatosis. Respective roles of iron and non-iron-related factors in 127 homozygous patients.

O Loréal1, Y Deugnier, R Moirand, L Lauvin, D Guyader, H Jouanolle, B Turlin, G Lescoat, P Brissot.   

Abstract

A retrospective study of 127 patients with untreated homozygous genetic hemochromatosis (HGH) was conducted to evaluate the respective roles of iron overload and non-iron-related factors in the development of hepatic fibrosis in HGH. Twenty-seven percent of the patients had cirrhosis, 21% had liver fibrosis and 52% had no fibrosis (prefibrotic group). The mean value of liver iron concentration was increased significantly (p < 0.001) in cirrhotic (378 +/- 144 mumol/g dry wt.) and in fibrotic (331 +/- 168) subjects compared to prefibrotic (237 +/- 108) patients. Of 13 patients with liver iron concentration > or = 500, 12 had liver fibrosis or cirrhosis, versus 48/134 with liver iron concentration < 500. Chronic alcoholic men exhibited hepatic fibrosis or cirrhosis more frequently than non-alcoholic men (p < 0.001). Non-alcoholic men had hepatic fibrosis or cirrhosis more often than non-alcoholic women (p < 0.05). Cirrhotic and fibrotic patients were significantly older than prefibrotic patients whilst a significant correlation between age and liver iron concentration was found in younger patients only. These results suggest that the iron overload threshold necessary to induce fibrosis is modulated by non-iron-related factors such as alcoholism, sex and age. The development of fibrosis in HGH with liver iron concentration < 500 mumol/g is frequent and must lead to a search for associated non-iron-related fibrogenic factors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1484146     DOI: 10.1016/s0168-8278(05)80104-7

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  11 in total

Review 1.  Liver iron content determination by magnetic resonance imaging.

Authors:  Konstantinos Tziomalos; Vassilios Perifanis
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

2.  Chronic iron overload in rats induces oval cells in the liver.

Authors:  P G Smith; G C Yeoh
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

3.  Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C.

Authors:  Richard W Lambrecht; Richard K Sterling; Deepa Naishadham; Anne M Stoddard; Thomas Rogers; Chihiro Morishima; Timothy R Morgan; Herbert L Bonkovsky
Journal:  Gastroenterology       Date:  2011-02-15       Impact factor: 22.682

Review 4.  Iron and iron-related proteins in alcohol consumers: cellular and clinical aspects.

Authors:  Kevin Ferrao; Najma Ali; Kosha J Mehta
Journal:  J Mol Med (Berl)       Date:  2022-10-10       Impact factor: 5.606

5.  Hemochromatosis: a model of metal-related human toxicosis.

Authors:  Pierre Brissot; Thibault Cavey; Martine Ropert; François Gaboriau; Olivier Loréal
Journal:  Environ Sci Pollut Res Int       Date:  2016-09-15       Impact factor: 4.223

Review 6.  [Hereditary hemochromatosis].

Authors:  Claus Niederau
Journal:  Med Klin (Munich)       Date:  2009-12-15

Review 7.  Alcohol Consumption in Concomitant Liver Disease: How Much is Too Much?

Authors:  Hannes Hagström
Journal:  Curr Hepatol Rep       Date:  2017-04-22

Review 8.  Low hepcidin in liver fibrosis and cirrhosis; a tale of progressive disorder and a case for a new biochemical marker.

Authors:  Driton Vela
Journal:  Mol Med       Date:  2018-03-15       Impact factor: 6.354

Review 9.  From Environment to Genome and Back: A Lesson from HFE Mutations.

Authors:  Raffaela Rametta; Marica Meroni; Paola Dongiovanni
Journal:  Int J Mol Sci       Date:  2020-05-15       Impact factor: 5.923

10.  Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.

Authors:  J B Porter; M S Elalfy; A T Taher; Y Aydinok; L L Chan; S-H Lee; P Sutcharitchan; D Habr; N Martin; A El-Beshlawy
Journal:  Ann Hematol       Date:  2012-10-21       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.